Table 1.
Patient characteristics at diagnosis.
| Patient Characteristics | ||
|---|---|---|
| Age, years, median (range) | 60 | (41–73) |
| Gender, male, n (%) | 5 | 56% |
| Histology Diffuse large B cell lymphoma (DLBCL), n (%) | 9 | 100% |
| De Novo, n (%) | 3 | 33% |
| Transformed DLBCL, n (%) | 6 | 64% |
| -from follicular lymphoma (FL), n (%) | 5 | 56% |
| -from marginal zone lymphoma (MZL), n (%) | 1 | 11% |
| Elevated LDH, n (%) | 9 | 100% |
| Disease Stage, n (%) | ||
| II | 2 | 22% |
| III | 3 | 33% |
| IV | 4 | 44% |
| IPI, n (%) | ||
| 3 (high-intermediate risk) | 5 | 56% |
| 4–5 (high risk) | 4 | 44% |
| Bone marrow infiltration, no of pts (%) | 5 | 56% |
| Infiltration, % of cells, median (range) | 50 | (10–90) |
| Bulky disease, n (%) | 2 | 22% |
| CNS infiltration, n (%) | 0 | 0% |
| B symptoms, n (%) | 1 | 11% |
| Immunohistochemistry CD20+, n (%) | 100% |
Elevated LDH: Lactate dehydrogenase > 480 U/L; IPI: International prognostic index; CNS: Central nervous system.